USFDA conducted an inspection at Zydus Lifesciences Limited's manufacturing facility SEZ-1 at Pharmez, Ahmedabad from March 20 to March 24, 2023, the company announced through an exchange filing. The inspection was a pre-approval inspection (PAI) and a GMP Audit that concluded with three observations.
The company said that there were no data integrity related observations and the company is addressing these observations.
Zydus received final approval from USFDA for Lubiprostone Capsules, the company announced on March 24.
Zydus Lifesciences shares
Bhandup BEST Bus Accident: Mumbai Sessions Court Denies Bail To Driver Santosh Sawant In Fatal Mishap That Killed 4
Hardik Pandya Hits Bullseye, DIRECT HIT To Run Out Kiwi Skipper Mitchell Santner In IND Vs NZ 4th T20I | VIDEO
Mumbai School To Function As Usual On Jan 29; MU Defers Today's Exams As State Mourns Ajit Pawar's Demise
Mumbai News: BMC To Build 580 Homes For Sanitation Workers In Chembur Under Ashray Yojana Phase II
The shares of Zydus Lifesciences on Friday closed at Rs 480.05, down by 0.47 per cent.
